Aims/hypothesis Glucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone secreted postprandially from enteroendocrine K cells, but despite therapeutically interesting effects, GIP physiology in humans remains incompletely understood. Progress in this field could be facilitated by a suitable GIP receptor antagonist. For the first time in humans, we investigated the antagonistic properties of the naturally occurring GIP(3-30)NH 2 in in vivo and in in vitro receptor studies. Methods In transiently transfected COS-7 cells, GIP(3-30)NH 2 was evaluated with homologous receptor binding and receptor activation (cAMP accumulation) studies at the glucagon-like peptide 1 (GLP-1), glucagon-like peptide-2 (GLP-2), glucagon, secretin and growth hormonereleasing hormone (GHRH) receptors. Ten healthy men (eligibility criteria: age 20-30 years, HbA 1c less than 6.5% [48 mmol/mol] and fasting plasma glucose [FPG] less than 7 mmol/l) were included in the clinical study. Data were collected as plasma and serum samples from a cubital vein cannula. As primary outcome, insulin secretion and glucose requirements were evaluated together with in a randomised, four-period, crossover design by infusing GIP(3-30)NH 2 (800 pmol kg
the glucagon-like peptide 1 (GLP-1), glucagon-like peptide-2 (GLP-2), glucagon, secretin and growth hormonereleasing hormone (GHRH) receptors. Ten healthy men (eligibility criteria: age 20-30 years, HbA 1c less than 6.5% [48 mmol/mol] and fasting plasma glucose [FPG] less than 7 mmol/l) were included in the clinical study. Data were collected as plasma and serum samples from a cubital vein cannula. As primary outcome, insulin secretion and glucose requirements were evaluated together with in a randomised, four-period, crossover design by infusing GIP(3-30)NH 2 (800 pmol kg −1 min ), a combination of these or placebo during hyperglycaemic clamp experiments. The content of the infusions were blinded to the study participants and experimental personnel. No study participants dropped out. Results GIP(3-30)NH 2 neither bound, stimulated nor antagonised a series of related receptors in vitro. The elimination plasma half-life of GIP(3-30)NH 2 in humans was 7.6 ± 1.4 min. Markedly larger amounts of glucose were required to maintain the clamp during GIP infusion compared with the other days. GIP-induced insulin secretion was reduced by 82% (p < 0.0001) during coinfusion with GIP(3-30)NH 2 , and the need for glucose was reduced to placebo levels. There were no effects of GIP(3-30)NH 2 alone or of GIP with or without GIP(3-30)NH 2 on plasma glucagon, GLP-1, somatostatin, triacylglycerols, cholesterol, glycerol or NEFA. GIP(3-30)NH 2 administration was well tolerated and without side effects. Conclusions/interpretation We conclude that GIP(3-30)NH 2 is an efficacious and specific GIP receptor antagonist in humans suitable for studies of GIP physiology and pathophysiology. Trial registration ClinicalTrials.gov registration no. NCT02747472. 
Introduction
Glucose-dependent insulinotropic polypeptide (GIP) is secreted from enteroendocrine K cells in response to intraluminal nutrients, in particular glucose and fat [1] . In the fasting state, the plasma concentration is negligible, but after food intake, it reaches 40-125 pmol/l in peripheral blood [1] . GIP is, like glucagon-like peptide-1 (GLP-1), an incretin hormone [2] , i.e. it potentiates glucose-induced insulin secretion in healthy individuals [3] .
GLP-1-based therapies are an important part of modern glucose-lowering treatment [4] , and the physiology of GLP-1 and its involvement in the pathophysiology of obesity and type 2 diabetes have been more intensively studied than that of GIP. One of the important tools in the elaboration of GLP-1 physiology and the development of GLP-1-based therapies is the GLP-1 receptor antagonist exendin(9-39), which was first described in 1991 [5] , and has been applied in multiple human studies since 1998 [6, 7] .
The insulinotropic effect of GIP is severely diminished among individuals with type 2 diabetes mellitus [8, 9] . However, GIP has other physiological effects, and has been shown to inhibit bone resorption [10] , increase adipose tissue blood flow and stimulate fat deposition [11, 12] . GIP(1-42) also affects intestinal blood flow [13] , and stimulates glucagon secretion at low blood glucose levels [14, 15] . The relative importance of GIP for the regulation of these processes remains unclear. A major reason for this has been the lack of a GIP receptor antagonist suitable for human studies.
Based on in vitro and rodent studies, many compounds have been proposed as suitable GIP receptor antagonists [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . However, due to remarkable species differences regarding the pharmacology of the GIP receptor system, transferability to humans is not simple; for instance, an acclaimed proline-substituted GIP analogue, Pro3(GIP), has antagonistic properties on rodent receptors, but is a full agonist of the human GIP receptor [16] .
GIP is processed from the precursor protein proGIP by the prohormone convertase type 1/3 (PC1/3) [26] . Another prohormone convertase, PC2, is present in pancreatic alpha cells [27] and in a K cell subpopulation [28] . The PC2-generated product of proGIP is GIP(1-30)NH 2 . This isoform acts on the human GIP receptor, a class B G protein-coupled receptor (GPCR), as a full agonist similar to GIP(1-42) [17, 29] . Both GIP isoforms are dipeptidyl peptidase 4 (DPP-4) substrates, and GIP(1-30)NH 2 is cleaved to GIP(3-30)NH 2 in the circulation. GIP(3-30)NH 2 does not stimulate the human GIP receptor, but acts as a potent and efficacious antagonist in vitro [17] .
Here, we present for the first time results on the antagonistic properties of GIP(3-30)NH 2 in humans. We evaluate the selectivity of GIP(3-30)NH 2 by receptor binding and activation studies in vitro at the GLP-1, glucagon-like peptide-2 (GLP-2), glucagon, secretin and growth hormonereleasing hormone (GHRH) receptors. During four 12 mmol/l hyperglycaemic clamps in healthy men, the effects on glucose-stimulated insulin secretion were evaluated during co-infusion of either GIP(1-42), GIP(3-30)NH 2 , GIP(1-42)+ GIP(3-30)NH 2 or placebo.
Methods
The protocol was approved by the Scientific-Ethical Committee of the Capital Region of Denmark (identification no. H-3-2013-007) and registered at ClinicalTrials.gov (registration no. NCT02747472) and the Danish Data Protection Agency (j.no. 2012-58-0004, local no. HGH-2015-031, I-Suite no. 03967).
Participants Ten healthy men (demographics shown in Table 1 ) were included after a screening visit. Inclusion criteria were age 20-30 years, HbA 1c less than 6.5% (48 mmol/mol) and fasting plasma glucose (FPG) less than 7 mmol/l. Exclusion criteria included acute or chronic illnesses, medication that could not be paused for 12 h, diabetes, first-degree relatives with diabetes, and abnormal blood haemoglobin levels, plasma liver enzymes (alanine and aspartate aminotransferases), plasma creatinine and urinary albumin/creatinine ratio. Written informed consent was obtained from all study participants before inclusion.
Peptides Synthetic GIP(1-42) (Clinalfa; Bachem, Bubendorf, Switzerland) and GIP(3-30)NH 2 (custom-synthesised; PolyPeptide Group, Strasbourg, France) were demonstrated to be over 97% pure and identical to the natural human peptide by HPLC, mass and sequence analysis. The peptides were dissolved in sodium chloride (9 mg/ml) with 0.2% human albumin (CSL Behring, Marburg, Germany) and sodium hydrogen carbonate with 0.2% human albumin, respectively, sterilised by filtration and microbiologically tested by the Capital Region Pharmacy (Herlev, Denmark) and stored at −20°C until use. On study days, the required amounts were thawed and prepared, under sterile conditions, for infusion by dilution to a total volume of 100 ml in sodium chloride for GIP and 250 ml for GIP(3-30)NH 2 . Placebo infusions were 100 ml and 250 ml sodium chloride, respectively.
Study design Participants were instructed not to consume alcohol or perform strenuous physical activity for 24 h before each study day. The study participants received GIP(1-42), GIP(3-30)NH 2 , both peptides or placebo infusions during a hyperglycaemic clamp in a randomised, double-blinded, crossover design. The content of the infusions were blinded to the study participants and experimental personnel. On each study day, the participants met after an overnight (10 h) fast. A cannula was placed in a cubital vein for blood sampling. The forearm and hand were wrapped in a heating pad (45°C) throughout the experiment to arterialise the blood. Another cannula was placed in the contralateral cubital vein for peptide and glucose infusions. At time 0 min, an infusion of GIP [32] were measured in plasma by RIAs as previously described. GIP(3-30)NH 2 was measured in plasma with an in-house-developed RIA using a polyclonal antibody (code no. 95234) raised in rabbits against human GIP(1-30)NH 2 and human GIP(1-30)NH 2 (catalogue no. 027-30; Phoenix Pharmaceuticals, Burlingame, CA, USA) as standard (a procedure similar to the GIP assay [31] ). The tracer was 125 I-labelled human GIP(1-42) (catalogue no. NEX402; Perkin Elmer, Skovlunde, Denmark). Plasma glucagon was measured by ELISA (10-1271-01; Mercodia, Uppsala, Sweden).
Materials for the in vitro studies
The receptor cDNAs for human wild-type GIP, GLP-1, glucagon, GLP-2, secretin and (Fig. 1a) using the standard stoichiometric chloramine T method previously described [33] . The labelled peptides were purified by HPLC.
Cell line and transfection COS-7 cells (American Type Culture Collection, Manassas, VA, USA) were grown in 10% CO 2 and at 37°C in DMEM 1885 supplemented with 10% FCS, 2 mmol/l glutamine, 180 units/ml penicillin and 45 g/ml streptomycin. Novel cells from the original cell stock were thawed when the passage number reached 40. The cells were further validated by phenotypic characterisation and transfection efficiency. A mycoplasma test was performed every third month on average. Receptor cDNA transfection of COS-7 cells was performed by the calcium phosphate precipitation method as previously described [34] . cAMP assay COS-7 cells were seeded in 96-well plates 1 day after transfection. The following day, the cells were washed once with HEPES-buffered saline (154 mmol/l NaCl) and incubated with HEPES-buffered saline and 1 mmol/l 3-isobutyl-1-methylxanthine for 30 min (37°C). To test for intrinsic activity, the endogenous ligands for each receptor (agonists) or GIP(3-30)NH 2 were added, and the plates were incubated for 30 min (37°C). To test GIP(3-30)NH 2 as an antagonist, the cells were preincubated for 10 min (37°C) with increasing concentrations of GIP(3-30)NH 2 , followed by 20 min incubation with a fixed concentration of agonist that binding to GIPR would result in 50-80% of maximal activation. Afterwards, the HitHunter cAMP XS-assay (DiscoveRx, Birmingham, UK) was carried out according to the manufacturer's instructions. All experiments were made in duplicate, and luminescence was measured by Perkin Elmer EnVision 2104 Multilabel reader.
Statistical analyses and calculations Based on our previous data [14] , a power calculation (probability [β] of 20% and level of statistical significance [α] of 5%) suggested that the inclusion of eight participants would be needed to be able to detect a minimum relevant difference of 25% in insulin secretion. To increase the power for evaluation of secondary outcomes and to decrease the risks of type 2 errors, ten participants were included.
Results are reported as mean ± SD unless otherwise stated. Calculations of the AUC were based on the trapezoidal rule and reported as incremental AUC (iAUC). Elimination halflife calculations were based on logarithmic (log 10 ) transformation of plasma concentrations and determination of the rate constant.
Statistical analyses were performed with GraphPad Prism 7.02 (GraphPad Software, San Diego, CA, USA). One-way repeated measures ANOVA with Greenhouse-Geisser correction and Tukey's multiple comparison were used to test for variations and differences between iAUC. A two-sided p value of < 0.05 was used as significance level. p values are summarised as *p < 0.05, **p ≤ 0.01 and ***p ≤ 0.001.
Insulin secretion rate (ISR) values were based on deconvolution of C-peptide concentrations, age, height, weight and population-based variables for C-peptide kinetics as previously described [35, 36] . The percentage inhibitory effect of GIP(3-30)NH 2 was calculated based on both iAUC values and peak values of insulin, C-peptide and ISR using the formula:
Results

Selectivity of GIP(3-30)NH 2 among human class B GPCRs
The affinity of GIP(3-30)NH 2 for the human GIP receptor is fivefold lower than that of GIP(1-42) as determined by homologous competition binding (Fig. 1b [17] ). In the present set-up, we reproduced these previous findings, demonstrating an affinity (K d ) of 3.0 nmol/l for GIP(3-30)NH 2 compared with the previously determined K d of 0.67 nmol/l for GIP . To evaluate the selectivity of GIP(3-30)NH 2 , we tested whether (Fig. 1c) . We identified only specific binding of 125 I-GIP(3-30)NH 2 to the human GIP receptor (Fig. 1d) . In parallel, as a validation of the presence and functionality of the receptors, we determined the cAMP responses to the agonists for these Fig. 2 Test of the functionality of GIP(3-30)NH 2 . cAMP production in response to the endogenous ligands and GIP(3-30)NH 2 (a-e), and antagonism of the endogenous ligands by GIP(3-30)NH 2 (f-j) for five related class B receptors. The studies were performed for the GLP-1 receptor (GLP-1R) (a, f), GLP-2 receptor (GLP-2R) (b, g), glucagon receptor (GCGR) (c, h), secretin receptor (SCTR) (d, i), and GHRH receptor (GHRHR) (e, j). Black circles, endogenous ligands; white squares, GIP(3-30)NH 2 ; black triangles, inhibition of endogenous ligand by GIP(3-30)NH 2 ; dashed lines, effect of GIP(3-30)NH 2 on GIP receptor. Data are shown as mean ± SEM. Conc., concentration; E max, maximum response (efficacy); GCG, glucagon; SCT, secretin receptors, and also tested whether increasing concentrations of GIP(3-30)NH 2 (up to 1 μmol/l) activated or inhibited the receptors (Fig. 2a-j Fig. 2f-j) but did not antagonise the responses of the agonists for the five related receptors. 2 In the clinical study, total GIP plasma levels reached steady state at 50-60 min with mean concentrations of 86 ± 20 pmol/l and 87 ± 22 pmol/l for the infusion of GIP(1-42) and GIP(1-42)+GIP(3-30)NH 2 , respectively (Fig. 3a) . As the total GIP RIA targets the C-terminus of the peptide, the elimination half-life of 17 ± 5.4 min illustrates the elimination of the sum of GIP(1-42) and the DPP-4 degradation product GIP .
Infusions of GIP(1-42) and GIP(3-30)NH
GIP(3-30)NH 2 reached steady state after less than 20 min (Fig. 3b) . The mean concentrations were 54 ± 12 nmol/l and 49 ± 9.8 nmol/l for the infusion of GIP(3-30)NH 2 and GIP(1-42)+GIP(3-30)NH 2 , respectively. The elimination half-lives for all study days appeared similar and equated to 7.6 ± 1.4 min.
The infusions did not affect the blood pressure or pulse rate during the infusion period or the following hour. No study participants experienced nausea, dizziness or other discomforts.
Glucose There were no significant differences between the plasma glucose levels on the study days, and the overall mean value during the clamp was 12.0 ± 1.18 mmol/l (Fig. 4a) . As illustrated in Fig. 4b , the amount of glucose infused to maintain the hyperglycaemic clamp was significantly higher during the GIP (1-42) Insulin, C-peptide and ISR There were no significant differences between the baseline values of insulin and Cpeptide on the four study days (Table 2) . GIP(1-42) markedly potentiated the glucose-stimulated insulin secretion [placebo, 8.1 ± 2.9 nmol/l × min; GIP(1-42), 29.3 ± 10.8 nmol/l × min], whereas GIP(3-30)NH 2 had no effect on insulin concentrations (6.6 ± 3.4 nmol/l × min) (Fig. 5a ). When GIP(1-42) was co-infused with GIP(3-30)NH 2 , the GIP(1-42)-induced potentiation of insulin secretion was dramatically and significantly reduced (12.4 ± 5.3 nmol/l × min), illustrating the GIP receptor-antagonising effect of GIP(3-30)NH 2 . There were small, but significant, differences between the insulin responses during combined GIP(1-42)+GIP(3-30)NH 2 infusions compared with GIP(3-30)NH 2 (p = 0.006), and with placebo infusions (p = 0.005). The inhibitory effect of GIP(3-30)NH 2 based on the iAUC for the whole infusion period (Fig.  5) , for the 10 min of steady-state levels of GIP(1-42) and for peak values, respectively, for insulin amounted to 80.7 ± 14.4%, 82.4 ± 12.8%, and 80.7 ± 16.0%. The same relation was seen with regard to C-peptide levels (Table 2) , based on which the inhibitory effect amounted to 74.8 ± 15.4% (iAUC 40 min ), 75.9 ± 15.1% (iAUC 10 min ) and 73.1 ± 14.9% (peak values). The calculated ISR (Table 2) showed an inhibitory effect of 78.2 ± 12.9% (iAUC 40 min ), 73.6 ± 14.8% (iAUC 10 min ) and 70.7 ± 15.7% (peak values).
Glucagon, somatostatin, GLP-1 and lipids There were no significant differences between the baseline values of the other pancreatic hormones glucagon or somatostatin. During the hyperglycaemic clamp, glucagon levels decreased similarly following glucose infusion on all study days (Fig. 6a) . Plasma somatostatin levels decreased slightly during the glucose infusion without significant differences between the four interventions (Fig. 6b) .
The baseline values of GLP-1 were not significantly different on the four study days. GLP-1 levels increased slightly during the glucose infusion without differences between the study days (Fig. 6c) .
To evaluate the possible effects of GIP(1-42) on fat deposition and lipid metabolism, cholesterols, triacylglycerols, NEFA and glycerol were measured. There were no significant differences between the baseline values, and during this short period there were no differences over time or between the responses to the four interventions (Fig. 6d-i) .
Discussion
On the basis of our previous in vitro studies [17, 37] , we hypothesised that GIP(3-30)NH 2 would be able to inhibit the GIP-induced potentiation of glucose-stimulated insulin secretion in humans. We found that GIP(3-30)NH 2 at an approximately 600-fold higher plasma concentration compared with GIP(1-42) antagonised the GIP receptor and resulted in an 82% inhibition of the GIP-potentiated glucosestimulated insulin secretion. Importantly, we also showed that GIP(3-30)NH 2 was highly selective for the human GIP receptor and did not bind to or stimulate closely (GLP-1, glucagon and GLP-2) or more distantly (secretin and GHRH) related receptors.
Calculation of the inhibitory effect We chose to calculate the inhibitory effect based on the iAUC of insulin and C-peptide. As insulin and C-peptide concentrations increased towards the end of each infusion experiment, which was most pronounced during the GIP(1-42) infusion, one may argue that longer experiments are needed to obtain a more precise estimate of the maximum inhibitory effect. If we evaluate the inhibitory effect based on the amount of glucose infused to perform the hyperglycaemic clamp, the day with co-infusion of GIP(3-30)NH 2 and GIP(1-42) was not significantly different from the placebo infusion. Nonetheless, since the same degree of inhibition was reached whether the calculations were based on iAUC [for both the 40 min period and for the last 10 min when plasma levels of GIP(1-42) and GIP(3-30)NH 2 had reached a steady state] or on peak values for insulin and C-peptide, we are confident that GIP(3-30)NH 2 inhibits GIP-induced insulin secretion by at least 80% during short-term hyperglycaemia.
Dosing Human studies with GIP(3-30)NH 2 have not been performed prior to these studies. The dosages of agonist and antagonist are obvious concerns as it is difficult to estimate the plasma concentrations needed for complete blockage of the target receptor. For selection of the GIP(1-42) infusion rate ), we aimed at postprandial levels (50-80 pmol/l). Based on the in vitro affinity data [17, 37] and inspired by human studies with the GLP-1 receptor antagonist exendin [38] [39] [40] , we estimated that an agonistantagonist relationship of around 500-fold would result in at least 50% inhibition of GIP-induced insulin secretion. It is possible that infusion of GIP(3-30)NH 2 at the chosen rate (i.e. 800 pmol kg
) would have an inhibitory effect during normal physiological circumstances of more than the calculated value of approximately 80% of the effects of endogenous postprandial GIP(1-42) levels as both the plasma glucose and GIP concentrations reached in this study were in the high postprandial range. As GIP(3-30)NH 2 is a competitive GIP receptor antagonist without agonistic properties, a sufficiently high antagonist/agonist ratio will block the GIP receptor completely.
GIP(3-30)NH 2 is GIP receptor selective It is crucial for the interpretation of our results and forthcoming studies that GIP(3-30)NH 2 is a selective GIP receptor antagonist without agonistic properties. The secretin receptor family and the endogenous ligands have similarities [41] [42] [43] that might allow interactions with GIP(3-30)NH 2 . GIP(1-42) may, in high concentrations, activate the GLP-1 receptor, and GLP-1 may also activate the GIP receptor. Indeed, the potent and widely used GLP-1 receptor antagonist exendin(9-39) is able to inhibit the GIP(1-42)-induced GIP receptor activation [42] . In contrast, GIP(3-30)NH 2 did not bind to the GLP-1 receptor or the other selected receptors and did not activate the GIP receptor [17] . GIP(3-30)NH 2 is therefore a selective GIP receptor antagonist in humans.
Compensatory mechanisms As a consequence of the interruption of important feedback mechanisms, hormone antagonism may stimulate the secretion of endogenous hormones. This is seen during exendin(9-39) infusions where the secretion of GLP-1 (and peptide YY from the same cells) increases rapidly [44, 45] , perhaps because of an inhibition of paracrine somatostatin secretion [46] . Another prominent example is the glucagon secretion following glucagon receptor antagonist administration, which is likely to be due to a feedback stimulation by amino acids [47] . However, during the short duration of these studies, there was no increase, not even a tendency towards an increase, in GIP secretion during antagonist administration.
Other effects of GIP(3-30)NH 2 GIP(3-30)NH 2 is the first GIP receptor antagonist used in humans, and in a subsequent study we have shown that the antagonist also inhibits triacylglycerol uptake in adipose tissue [48] . This confirmed that GIP(1-42) increases adipose tissue blood flow and triacylglycerol deposition via the GIP receptor and demonstrated that GIP(3-30)NH 2 can inhibit these processes. Under the present study conditions, infusion of GIP(3-30)NH 2 was not associated with any changes in peripheral plasma lipid concentrations consistent with the lack of acute effects of GIP on these variables, as previously reported [49] . Importantly, the antagonist did not elicit any side effects or discomfort.
Future studies Our studies suggest that GIP(3-30)NH 2 may be useful to antagonise the actions of endogenous GIP, and future studies should therefore be devoted to unravelling the many uncertainties regarding the physiological roles of GIP [50] . Such studies could imply a mixed meal test or administration of glucose, which will stimulate Conclusions The naturally occurring GIP receptor-specific antagonist GIP(3-30)NH 2 is well tolerated and inhibits GIPpotentiated glucose-stimulated insulin secretion by 82% under the chosen experimental conditions. The peptide is therefore a new scientific tool that can facilitate future studies of GIP. had full access to all of these data and take responsibility for the integrity of the data and accuracy of the data analysis. LSG and MMR are guarantors of the in vitro part of the study, had full access to all of these data and take responsibility for the integrity of the data and accuracy of the data analysis.
